Integrative Cancer Care in China: How TCM and Modern Oncology Work Together

Quick Answer: China is the only country where Traditional Chinese Medicine (TCM) and modern oncology operate at full institutional depth within the same hospital system. A meta-analysis of 65 clinical trials (4,751 patients) found that adding astragalus-based herbal medicine to platinum chemotherapy improved 12-month survival in non-small cell lung cancer patients (McCulloch et al., 2017). A 2024 randomized controlled trial showed the Chinese herbal formula JianPi-BuShen increased chemotherapy completion rates from 47.6% to 63.0% in colon cancer patients (Sun et al., 2024). The China Anti-Cancer Association's 2025 Integrative Cancer Guidelines now cover 53 cancer types and 60 treatment modalities. International patients can access this integrative model at 50-70% lower cost than comparable oncology care in the United States or Japan.

Cancer treatment is not just about killing tumor cells. It is about keeping the patient strong enough to complete treatment, managing the devastating side effects that cause patients to abandon therapy, recovering immune function after each cycle of chemotherapy, and maintaining the quality of life that makes fighting worthwhile.

This is where China's approach to cancer care diverges fundamentally from the rest of the world. In Chinese Grade 3A hospitals — the country's top-tier medical institutions — oncology departments and TCM departments do not merely coexist. They co-manage patients through coordinated treatment protocols, joint consultations, and integrated care plans that combine the precision of Western oncology with the systemic support of Traditional Chinese Medicine.

This is not folk medicine practiced alongside science. It is a national healthcare strategy backed by government policy, governed by clinical guidelines, and increasingly supported by randomized controlled trial evidence. For international patients — especially those from Japan, where interest in integrative approaches runs deep — understanding this model opens a door to cancer care options that simply do not exist elsewhere.

What Does Integrative Oncology Actually Mean in China?

Beyond "Complementary" Medicine

In most Western countries and in Japan, the relationship between conventional oncology and traditional medicine follows a parallel model. Patients receive chemotherapy from their oncologist, then visit a separate acupuncture clinic or herbal practitioner on their own initiative. There is little coordination between the two sides. The oncologist may tolerate the patient's TCM use, but rarely prescribes it or monitors it as part of the treatment plan.

China's model is fundamentally different. The Chinese government has promoted the integration of Western medicine and TCM since the founding of the People's Republic, and this institutional commitment accelerated under the "14th Five-Year Plan" and the "Healthy China 2030" initiative. The result is a system where:

• Oncologists and TCM physicians share the same medical record and consult on cases together
• TCM is prescribed alongside chemotherapy on the same treatment order, not as a separate afterthought
• Herbal formulas are adjusted in real time based on the patient's blood counts, imaging results, and treatment side effects
• National clinical guidelines formally specify when and how to integrate TCM with each cancer type and treatment modality
• Hospital pharmacies stock standardized herbal preparations subject to quality control, batch testing, and pharmacovigilance

The China Anti-Cancer Association (CACA) has developed the "Chinese Integrated Cancer Diagnosis and Treatment Guidelines," involving over 13,000 specialists between 2022 and 2025. The 2025 edition, launched at the Xi'an Integrative Oncology Conference, covers 53 cancer types and 60 treatment modalities. These are not vague wellness recommendations — they are structured clinical protocols comparable in specificity to NCCN or ESMO guidelines.

The Theoretical Framework

China's integrative oncology operates on a principle called "Fu Zheng Qu Xie" — support the body's righteous energy while eliminating pathogenic factors. In practical clinical terms, this translates to a dual-track approach:

The two tracks are not competing philosophies — they are complementary strategies targeting different aspects of the same disease. Western oncology attacks the cancer. TCM supports the patient who is enduring the attack.

Clinical Evidence: What Does the Research Actually Show?

The most common criticism of integrative oncology is that it lacks rigorous evidence. This criticism was once valid. It is no longer accurate for several key TCM applications in cancer care. While evidence quality varies by modality and cancer type, the volume of randomized controlled trial data from China and international institutions is now substantial.

Herbal Medicine + Chemotherapy: Survival and Completion Rates

Astragalus-Based Formulas in Lung Cancer

The most extensively studied herbal compound in integrative oncology is Astragalus membranaceus (Huang Qi). A landmark meta-analysis published in Integrative Cancer Therapies reviewed 65 randomized clinical trials enrolling 4,751 patients with non-small cell lung cancer (NSCLC). The analysis found that adding astragalus-based herbal preparations to platinum-based chemotherapy was associated with:

• Improved 12-month, 24-month, and 36-month survival rates
• Enhanced tumor response rates
• Improved Karnofsky Performance Status scores (a measure of functional capacity)

(McCulloch et al., 2017)

A 2025 meta-analysis focused specifically on cancer-related fatigue found that Astragalus membranaceus significantly reduced fatigue severity (SMD = -1.63, 95% CI [-1.90, -1.36], P < .00001) and improved quality of life across eight randomized controlled studies (Sheng et al., 2025).

The effect appears to be immunomodulatory — astragalus enhances natural killer cell activity, potentiates lymphocyte-activated killer (LAK) cell function, and helps restore T-cell function suppressed by chemotherapy.

JianPi-BuShen Formula in Colon Cancer

A rigorously designed 2024 randomized, placebo-controlled trial published in the European Journal of Cancer tested the JianPi-BuShen herbal formula in 376 patients with stage II and III colon cancer undergoing adjuvant chemotherapy. The results were striking:

(Sun et al., 2024)

This is a critical finding. Chemotherapy works only if patients can complete the prescribed course. When severe side effects force dose reductions or early termination, cancer outcomes worsen. A herbal formula that increases completion rates by 15 percentage points directly translates to better survival probability.

Astragalus-Based Formulas in Colorectal Cancer

A meta-analysis of 22 studies involving 1,409 colorectal cancer patients found that Astragalus-based Chinese medicines combined with chemotherapy significantly improved tumor response rates (RR: 1.52; 95% CI: 1.24-1.87; P < 0.0001) and quality of life based on Karnofsky Performance Status scores (RR: 2.51) (Deng et al., 2019).

YIV-906 (PHY906): From Ancient Formula to FDA-Tracked Drug

Perhaps the most compelling example of TCM-inspired integrative oncology is YIV-906, a botanical drug candidate derived from an 1,800-year-old four-herb formula. Developed at Yale University by Dr. Yung-Chi Cheng and granted FDA orphan drug designation in 2018 for hepatocellular carcinoma, YIV-906 has been tested in nine clinical trials across liver, pancreatic, and colorectal cancers.

A Phase II trial combining PHY906 with capecitabine in advanced hepatocellular carcinoma demonstrated a 46.2% stable disease rate and 6-month median overall survival, with notably reduced non-hematological toxicities compared to chemotherapy alone (Changou et al., 2021).

In 2025, Phase 2b results presented at both ASCO and ESMO GI showed that YIV-906 plus sorafenib improved both efficacy and tolerability in HBV-positive advanced HCC patients compared to sorafenib monotherapy. Preclinical data demonstrated that YIV-906 enhanced anti-PD1 immunotherapy action, completely eradicating tumors in mouse models through enhanced adaptive and innate immunity (Liu et al., 2021).

YIV-906 demonstrates a principle that underpins Chinese integrative oncology: traditional formulas are not magic — they are complex mixtures of bioactive compounds whose mechanisms can be characterized through modern pharmacology.

Acupuncture in Cancer Supportive Care

Chemotherapy-Induced Nausea and Vomiting

Acupuncture for chemotherapy-induced nausea and vomiting (CINV) has the strongest evidence base of any TCM application in oncology. The American Society of Clinical Oncology (ASCO) and the Society for Integrative Oncology (SIO) jointly recommended acupuncture for CINV in their 2022 clinical practice guideline — a landmark endorsement (Mao et al., 2022).

The mechanism is well-characterized: stimulation of the P6 (Neiguan) acupoint on the inner wrist modulates vagal nerve signaling, reduces gastric dysrhythmia, and enhances serotonin receptor regulation. Electroacupuncture at P6 has been shown to significantly decrease emesis episodes compared to both minimal needling and antiemetic drugs alone.

Cancer Pain Management

A 2020 systematic review and meta-analysis published in JAMA Oncology analyzed evidence from multiple randomized controlled trials and concluded that acupuncture and acupressure were associated with significantly improved cancer pain outcomes (He et al., 2020). A 2024 network meta-analysis of 24 acupuncture modalities for cancer pain found that specific combinations — particularly acupuncture combined with moxibustion — were superior to pharmacological treatment alone for both pain reduction and quality of life improvement (PMC, 2025).

A 2024 multicenter randomized clinical trial comparing acupuncture versus massage in 298 patients with advanced cancer found that acupuncture was associated with sustained long-term pain reduction, improved fatigue, better sleep, and enhanced quality of life over 26 weeks (Liou et al., 2024).

Chemotherapy-Induced Peripheral Neuropathy

Peripheral neuropathy — numbness, tingling, and pain in hands and feet — is one of the most distressing and persistent side effects of taxane and platinum-based chemotherapy. Multiple RCTs have demonstrated that acupuncture can alleviate neuropathic pain and improve sensory thresholds in cancer patients (Bao et al., 2018).

Non-Pharmacological TCM for Chemotherapy Side Effects

A 2025 Bayesian network meta-analysis of randomized controlled trials found that non-pharmacological TCM interventions — including acupuncture, electroacupuncture, and moxibustion — significantly improved gastrointestinal function and quality of life in patients undergoing chemotherapy. The study concluded that these modalities "viably complement standard pharmacological treatments" (Yang et al., 2025).

Qi Gong and Tai Chi: Mind-Body Interventions

Qi gong and tai chi are routinely prescribed in Chinese cancer rehabilitation programs. A systematic review and meta-analysis published in the Journal of Cancer Survivorship evaluated 15 RCTs involving 1,283 cancer survivors and found statistically significant improvements in:

(Wayne et al., 2018)

A study published in JAMA Oncology found that tai chi demonstrated greater benefit than aerobic exercise for sleep quality and showed notably higher improvement in survival among patients with advanced lung cancer — a finding that warrants further investigation in larger trials.

An updated 2019 meta-analysis confirmed statistically significant and clinically meaningful effects of qi gong and tai chi for fatigue and sleep quality in cancer survivors (Zeng et al., 2019).

Herbal Medicine for Specific Side Effects

Chemotherapy-Induced Thrombocytopenia

Low platelet counts (thrombocytopenia) frequently force chemotherapy dose reductions or terminations. A 2025 randomized controlled trial found that Danggui Buxue Decoction (DBD) prevented further chemotherapy-induced thrombocytopenia and minimized its adverse effects on chemotherapy scheduling, including dose downregulation and regimen changes (Liu et al., 2025).

Separately, a randomized multicenter study of Xiaoaiping herbal injections in 140 patients with lung and gastric cancer demonstrated improved platelet recovery during chemotherapy (Yang et al., 2019).

Cancer-Related Fatigue

A systematic review of 10 randomized clinical trials involving 751 participants found that Chinese herbal medicine used alone or combined with chemotherapy showed significant relief in cancer-related fatigue compared to controls. Quality of life also improved, and no severe adverse effects were reported (Xu et al., 2014).

Breast Cancer Chemotherapy Side Effects

A 2024 meta-analysis concluded that traditional Chinese medicine combined with chemotherapy was superior to chemotherapy alone in improving therapeutic effective rates after breast cancer surgery, reducing adverse reactions, and enhancing immune function (Wang et al., 2024).

Which Cancers Respond Best to Integrative Treatment?

Not all cancers benefit equally from TCM integration. Based on the available evidence and clinical practice in China's leading oncology centers, here is a practical assessment:

Important caveat: TCM integration shows the strongest evidence as supportive care — improving treatment tolerance, reducing side effects, and enhancing quality of life. For direct anti-tumor effects, the evidence remains preliminary and should not be used as a basis for treatment decisions independent of conventional oncology.

TCM Modalities Used in Chinese Integrative Oncology

Chinese Herbal Medicine (Zhong Yao)

Herbal medicine is the primary therapeutic modality in Chinese integrative oncology. Unlike Western herbal supplements, which typically involve single standardized extracts, Chinese herbal prescriptions are multi-herb formulas customized to the individual patient's condition, constitution, and treatment phase.

Common herbal strategies in oncology:

• Fu Zheng (immune support): Astragalus (Huang Qi), Ginseng (Ren Shen), Codonopsis (Dang Shen), Reishi mushroom (Ling Zhi) — used to bolster white blood cell counts, NK cell activity, and T-cell recovery during chemotherapy
• Jian Pi (spleen-strengthening): Atractylodes (Bai Zhu), Poria (Fu Ling), Chinese yam (Shan Yao) — used to address chemotherapy-induced digestive dysfunction, appetite loss, and fatigue
• Huo Xue (blood-activating): Salvia (Dan Shen), Angelica (Dang Gui) — used to improve microcirculation, reduce thrombosis risk, and enhance drug delivery to tumor sites
• Qing Re Jie Du (heat-clearing, detoxifying): Scutellaria (Huang Qin), Hedyotis (Bai Hua She She Cao), Oldenlandia — used for anti-inflammatory support and in some protocols for direct anti-tumor activity

In Chinese hospitals, these formulas are prescribed by credentialed TCM physicians who review the oncologist's treatment plan, monitor blood work, and adjust herbal prescriptions based on the patient's changing condition. Herbal preparations are dispensed through the hospital pharmacy, subject to quality assurance standards. This institutional oversight is what distinguishes China's herbal oncology from self-prescribed supplements purchased online.

Standardized injectable herbal preparations are also widely used in Chinese oncology, including:

• Shenqi Fuzheng Injection (Astragalus + Codonopsis) — approved by China's NMPA for immune support during chemotherapy
• Kanglaite Injection (Coix seed extract) — studied in multiple RCTs for lung and liver cancer
• Huachansu Injection (toad venom extract) — used for liver and pancreatic cancer

Acupuncture and Moxibustion

Acupuncture is the most evidence-supported TCM modality in cancer care. In Chinese oncology departments, acupuncture treatments are typically provided in dedicated treatment rooms within the same ward or building.

Primary applications:

Moxibustion — the application of burning mugwort (Artemisia) near acupuncture points to generate warmth — is commonly used alongside acupuncture, particularly for:

• Immune function support (raising white blood cell counts)
• Digestive recovery after abdominal surgery
• Cold-type pain syndromes
• General fatigue and debility

Qi Gong and Tai Chi

In China's cancer hospitals and rehabilitation centers, qi gong is not an optional wellness extra — it is a prescribed therapeutic intervention. Many hospitals employ dedicated qi gong instructors, and group practice sessions are scheduled as part of the treatment protocol.

Guolin Qi Gong, developed specifically for cancer patients in the 1970s, is the most widely practiced form. It combines walking meditation, coordinated breathing, and gentle movement. The Shanghai Cancer Recovery Association has promoted Guolin Qi Gong as a core element of cancer rehabilitation for decades.

Clinical evidence supports its use for fatigue reduction, sleep improvement, depression management, and quality of life enhancement, as detailed in the research section above.

TCM Dietary Therapy (Shi Liao)

Chinese integrative oncology includes structured dietary guidance based on TCM nutritional principles. This goes beyond Western nutritional advice — it classifies foods by their thermal nature (warming, cooling, neutral) and therapeutic actions, prescribing specific dietary modifications for each treatment phase:

• During chemotherapy: Easily digestible, spleen-strengthening foods (congee with Chinese yam, red dates, millet). Avoidance of cold and raw foods that may exacerbate nausea.
• During radiation: Yin-nourishing foods to counteract the "heat" of radiation (pear, lily bulb, tremella mushroom, lotus seed).
• Post-surgery recovery: Qi and blood-building foods (bone broth, black chicken, astragalus-fortified soups).
• Long-term maintenance: Anti-inflammatory, immune-supporting foods tailored to constitution.

How to Choose a Hospital for Integrative Cancer Care in China

Not all Chinese hospitals offer the same quality of integrative oncology. International patients should prioritize hospitals that meet specific criteria:

Hospital Selection Criteria

1. Grade 3A designation — China's highest hospital tier, indicating comprehensive departments, research capacity, and quality oversight
2. Dedicated international patient department — with English or Japanese-speaking coordinators, separate registration, and internationally formatted medical records
3. Both oncology and TCM departments at provincial or national ranking — a hospital excellent in oncology but weak in TCM (or vice versa) cannot deliver true integration
4. Participation in CACA integrative guidelines development — indicates the hospital's TCM oncology team is aligned with national evidence-based protocols
5. Published clinical research — hospitals contributing to the evidence base are more likely to practice evidence-based integrative care

Leading Hospitals for Integrative Cancer Care

For patients specifically interested in advanced Western oncology treatments like CAR-T cell therapy or proton beam radiation, Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center offer both cutting-edge Western treatment and robust TCM integration. For patients prioritizing the TCM component — perhaps seeking herbal medicine expertise or extensive acupuncture protocols — Guangdong Provincial Hospital of Chinese Medicine and Longhua Hospital are stronger choices.

For a broader overview of Shanghai's top international hospitals, see our dedicated guide.

The Patient Journey: What to Expect

Before Arrival

1. Medical records preparation: Compile all pathology reports, imaging (CT, MRI, PET-CT), genetic testing results (if available), and treatment history. Have these translated into Chinese by a certified medical translator. OriEast provides this service as part of patient coordination.

2. Remote consultation: Many Chinese hospitals offer telemedicine consultations where both an oncologist and a TCM physician review your case. This determines whether integrative care is appropriate and which hospital is the best fit.

3. Visa and logistics: International patients typically enter on a medical visa (S1 or S2) for treatment stays longer than 30 days. For shorter consultations, visa-free entry may be available depending on nationality. See our medical tourism planning guide for detailed logistics.

Week 1: Assessment and Treatment Planning

• Day 1-2: Registration at international patient department. Comprehensive diagnostic workup including blood panels, tumor markers, imaging review or new scans, and pathology review.
• Day 2-3: Oncology consultation. The attending oncologist reviews all results and proposes a Western treatment plan (surgery, chemotherapy regimen, immunotherapy, targeted therapy, radiation — or combinations).
• Day 3-4: TCM consultation. A senior TCM physician conducts a full TCM assessment — pulse diagnosis, tongue examination, symptom pattern differentiation — and proposes supportive TCM interventions aligned with the Western treatment plan.
• Day 4-5: Integrated care conference. The oncology and TCM teams review the combined treatment plan, check for potential herb-drug interactions, and finalize the protocol.

Treatment Phase

The integrated treatment schedule typically runs concurrently:

• Chemotherapy/immunotherapy cycles proceed on the standard schedule (e.g., every 2-3 weeks)
• Herbal medicine is prescribed in between cycles, adjusted before each new cycle based on blood counts and side effect profile
• Acupuncture sessions are scheduled 2-3 times per week, timed to address anticipated side effects (e.g., nausea sessions scheduled 24-48 hours after chemotherapy)
• Qi gong instruction begins early in the treatment period, with group or individual sessions 3-5 times per week
• Dietary guidance is provided by the TCM team and updated as treatment progresses

Post-Treatment and Follow-Up

After completing the primary treatment course, many international patients return home with:

• A detailed bilingual treatment summary
• Continued herbal medicine prescription (often shipped internationally or sourced locally with guidance)
• Qi gong practice instructions for continued home practice
• Follow-up schedule coordinated between the Chinese treatment team and the patient's home oncologist

For patients who want a comprehensive health assessment before returning home, Shanghai offers excellent executive health checkup programs.

Cost Comparison: Integrative Cancer Care

One of the most significant advantages of China's integrative model is cost. Not only are individual treatments less expensive, but the integrative approach itself can reduce total cost by preventing treatment interruptions, reducing emergency hospital admissions for side effects, and lowering supportive medication needs.

Treatment Cost Comparison (2025-2026 Estimates, USD)

TCM Integrative Component Costs (China)

The total TCM component typically adds $2,000-5,000 to a 3-month cancer treatment course — a modest increment that may substantially improve treatment outcomes, quality of life, and treatment completion rates.

Total Cost Scenario: Stage III Colon Cancer (6 Months)

Note: These are approximate ranges. Actual costs vary based on specific drugs used, hospital tier, complications, and individual treatment plans.

China vs. Japan vs. United States: Approaches to Integrative Oncology

For Japanese patients — who represent a significant proportion of international cancer patients seeking care in China — understanding the differences between these three systems is particularly relevant.

Structural Comparison

Key Difference for Japanese Patients

Japanese oncology is excellent — among the best in the world for many cancer types. Japan also has its own tradition of integrative medicine through Kampo (Japanese herbal medicine derived from Chinese medicine). However, Kampo in Japan operates within significant constraints:

• Formulas are pre-standardized (approximately 130 formulas approved by Japan's Ministry of Health)
• Customization is limited compared to Chinese herbal practice
• Integration with oncology is dependent on individual oncologists, not institutional protocol
• The scope of Kampo is narrower than the full TCM toolkit available in China

China offers Japanese patients something unavailable at home: fully individualized herbal formulas, prescribed by specialized TCM oncologists, administered under the same roof as world-class Western oncology, at a fraction of the cost of Japanese cancer care. The cultural and culinary similarities between China and Japan also make the transition easier than traveling to Western countries for treatment.

Real-World Patient Scenarios: How Integration Works in Practice

To illustrate how the integrative model operates in practice, consider these representative clinical scenarios based on common treatment patterns at Chinese Grade 3A cancer hospitals.

Scenario 1: Early-Stage Breast Cancer (Stage IIA)

A 52-year-old patient undergoes lumpectomy followed by adjuvant chemotherapy (AC-T regimen: doxorubicin/cyclophosphamide followed by paclitaxel). The Western oncology protocol is standard — four cycles of AC followed by four cycles of taxane.

The TCM physician conducts an initial assessment and identifies a pattern of qi deficiency with blood stasis. The integrative protocol includes:

• Herbal medicine phase 1 (during AC cycles): Astragalus-based formula with Codonopsis and Atractylodes to support white blood cell counts and reduce nausea. Formula is paused 48 hours before and after each infusion to avoid any potential interaction.
• Acupuncture: P6 (Neiguan) electroacupuncture on the day before and day after each infusion for nausea prevention. ST36 (Zusanli) and SP6 (Sanyinjiao) twice weekly for fatigue management.
• Herbal medicine phase 2 (during taxane cycles): Formula modified to include blood-nourishing herbs (Angelica, Rehmannia) and nerve-protective herbs to reduce peripheral neuropathy risk.
• Qi gong: Guolin walking qi gong introduced from week 2, practiced daily for 30 minutes.
• Dietary therapy: Warming, spleen-strengthening foods during AC phase; yin-nourishing foods during taxane phase to counteract heat toxicity.

The goal: complete all eight chemotherapy cycles without dose reduction, minimize side effects that reduce quality of life, and maintain functional capacity for faster post-treatment recovery.

Scenario 2: Advanced Non-Small Cell Lung Cancer (Stage IIIB)

A 67-year-old patient with squamous cell lung cancer receives concurrent chemoradiation (carboplatin/paclitaxel + thoracic radiation) followed by durvalumab immunotherapy consolidation.

The integrative component addresses the combined toxicity of chemotherapy and radiation:

• Herbal medicine: Yin-nourishing, lung-moistening formula to reduce radiation pneumonitis risk and manage radiation esophagitis. Includes Ophiopogon (Mai Dong), Lily bulb (Bai He), and Scutellaria (Huang Qin) for anti-inflammatory support.
• Acupuncture: Targeted at radiation-induced dry mouth (xerostomia), chest tightness, and cancer-related fatigue. Three sessions per week during the 6-week radiation course.
• Moxibustion: Applied to ST36 and CV6 (Qihai) to support immune recovery between chemoradiation and immunotherapy initiation.
• Qi gong: Modified sitting qi gong for patients with limited exercise tolerance. Focus on breathing exercises to maintain pulmonary function.

Scenario 3: Post-Treatment Cancer Survivorship

A 45-year-old patient who completed treatment for stage II colon cancer (surgery + 6 months FOLFOX chemotherapy) in Japan seeks integrative rehabilitation in China for persistent cancer-related fatigue, chemotherapy-induced peripheral neuropathy, and anxiety about recurrence.

This survivorship-focused integrative program might last 2-4 weeks:

• Herbal medicine: Spleen and kidney-strengthening formula for fatigue and digestive recovery. Specific herbs targeting nerve regeneration (Astragalus, Millettia).
• Acupuncture: Intensive course (daily for 2 weeks, then 3 times weekly) targeting peripheral neuropathy in hands and feet, using Ba Feng and Ba Xie points plus local needling.
• Qi gong: Daily Guolin walking qi gong and Five Animal Frolics for reconditioning.
• Psychological support: Mind-body integration through meditation-based qi gong, addressing cancer-related anxiety.
• Dietary consultation: Long-term anti-inflammatory dietary plan based on TCM constitution assessment.

These scenarios demonstrate that integrative oncology in China is not a single intervention — it is a coordinated care strategy that adapts to the patient's cancer type, treatment phase, and individual needs.

Understanding the Limits: What TCM Cannot Do

Responsible integrative oncology requires honest communication about limitations. TCM in cancer care does not:

• Cure cancer. No TCM modality has been proven to eliminate malignant tumors as a standalone treatment. Patients who choose TCM instead of conventional treatment are making a dangerous decision.
• Replace chemotherapy, surgery, radiation, immunotherapy, or targeted therapy. TCM is supportive and complementary. It works alongside these treatments, not instead of them.
• Work for every patient. Individual responses vary. Some patients experience significant benefit from herbal medicine and acupuncture; others notice minimal effect.
• Come without risk. Herb-drug interactions are real. Some Chinese herbs can affect liver metabolism of chemotherapy drugs or alter blood clotting. This is precisely why institutional integration — where TCM physicians and oncologists share information — is safer than self-prescribed herbal supplements.
• Guarantee improved survival. While meta-analyses show population-level improvements in survival and response rates, individual outcomes are not predictable.

Any practitioner or facility that promises TCM can cure cancer should be avoided. The value of TCM in oncology is in making the fight more bearable, the treatment more completable, and recovery more achievable.

How to Learn More About Acupuncture and Herbal Medicine for Cancer Support

For patients interested in specific TCM modalities used in cancer care, our detailed guide on acupuncture and herbal medicine for cancer support covers the evidence for each modality, what to expect during treatment sessions, and how to evaluate practitioners.

For those considering China specifically for advanced Western oncology treatments that can be combined with TCM, our guides on CAR-T cell therapy costs and access and proton beam therapy provide detailed information. Both of these cutting-edge treatments are available at hospitals with strong TCM integration.

Patients planning their first trip for medical care in China should start with our complete medical tourism guide, which covers visa logistics, accommodation, communication, payment, and follow-up care coordination.

Frequently Asked Questions

Is integrative cancer care in China safe for international patients?

Yes, when received at Grade 3A hospitals with dedicated international patient departments. These hospitals follow standardized treatment protocols, employ English or Japanese-speaking coordinators, and provide internationally formatted medical records. The integrative approach is structured and monitored — herbal prescriptions are checked against the chemotherapy regimen for potential interactions. The key safety factor is institutional integration: receiving TCM within the same hospital system as your oncology care, not from an unregulated external source.

Can I receive integrative cancer treatment if I have already started chemotherapy in my home country?

Yes. Many international patients arrive mid-treatment. Chinese integrative oncology teams are experienced in joining an ongoing treatment course. You would bring your complete medical records, and the TCM physician would design a supportive protocol to complement your existing chemotherapy regimen. Herbal formulas can be adjusted to target the specific side effects you are experiencing. Some patients travel to China specifically for the TCM component while continuing their Western treatment schedule.

Will Chinese herbal medicine interfere with my chemotherapy drugs?

Potential herb-drug interactions are a legitimate concern and the primary reason why institutional integration matters. In China's Grade 3A hospitals, TCM physicians are trained in pharmacology and review the oncologist's prescription before finalizing herbal formulas. Known problematic interactions are avoided, and formulas are adjusted or paused during critical treatment windows (e.g., 48 hours before and after certain chemotherapy agents). This is fundamentally different from self-prescribing herbal supplements without medical oversight.

How long do I need to stay in China for integrative cancer treatment?

This depends entirely on the treatment plan. Typical scenarios include:

• Initial assessment and treatment planning: 1-2 weeks
• Full chemotherapy course with TCM integration: 3-6 months (with possible trips home between cycles)
• Post-treatment rehabilitation: 2-4 weeks
• Second opinion with integrated treatment recommendation: 5-7 days

Many patients establish the treatment protocol in China, then receive ongoing herbal prescriptions remotely while completing treatment at home. OriEast coordinates the logistics for continued care across borders.

Does insurance cover integrative cancer care in China?

Chinese national medical insurance does not cover international patients. Most treatment is self-pay. However, some international health insurance plans and medical tourism insurance policies cover treatment at accredited Chinese hospitals. Japanese patients should check with their insurer — some policies cover overseas treatment for cancers where the treatment is not available domestically. The significant cost savings compared to treatment in the US or Japan mean that even self-paying patients often spend less total than they would with insurance co-pays in their home country.

Is the quality of chemotherapy drugs in China the same as in the US or Japan?

Yes. China's major cancer hospitals use the same international-standard chemotherapy agents (manufactured by the same global pharmaceutical companies or Chinese bioequivalent manufacturers that have passed NMPA approval). For targeted therapies and immunotherapies, many drugs are the same products available globally (pembrolizumab, nivolumab, bevacizumab, etc.), often at dramatically lower prices due to China's national drug procurement negotiations. China also has access to domestically developed immunotherapy drugs (such as sintilimab and tislelizumab) that have shown comparable efficacy in large clinical trials.

What makes China's integrative approach different from Kampo in Japan?

While both China and Japan draw from the same historical medical tradition, the clinical application differs in important ways. Japan's Kampo system uses approximately 130 pre-standardized herbal formulas, which oncologists can prescribe directly. China's TCM system allows fully individualized herbal prescriptions — a TCM physician can modify any formula, combine multiple approaches, and adjust the prescription in real time based on the patient's changing condition. Additionally, Chinese integrative oncology encompasses a broader toolkit (acupuncture, moxibustion, qi gong, dietary therapy, herbal injections) all coordinated within the hospital system. For patients who have tried Kampo without sufficient benefit, China's more comprehensive approach may offer additional options.

Can integrative treatment help with cancers that have not responded to standard therapy?

For patients with treatment-resistant or advanced cancers, China's integrative model offers several potential avenues. On the Western oncology side, China provides access to CAR-T clinical trials (including solid tumor trials not available elsewhere), novel immunotherapy combinations, and proton beam therapy. On the TCM side, integrative support can help maintain quality of life, manage pain, support nutritional status, and preserve functional capacity — all of which matter profoundly when curative treatment is no longer the primary goal. TCM's emphasis on patient-centered, holistic care becomes especially valuable in the palliative and supportive setting.

Safety Considerations and Herb-Drug Interactions

The question of safety is paramount for any cancer patient considering integrative treatment. It is also the area where China's institutional model provides the greatest advantage over self-directed integrative approaches.

Known Interaction Categories

TCM physicians in Chinese cancer hospitals are trained to recognize several categories of potential herb-drug interactions:

Cytochrome P450 interactions: Some Chinese herbs — particularly those containing berberine (Huang Lian), St. John's Wort equivalents, and certain flavonoid-rich herbs — can affect the liver enzymes (CYP3A4, CYP2D6, CYP1A2) responsible for metabolizing chemotherapy drugs. Altered metabolism can either increase drug toxicity or reduce drug efficacy. In the integrated hospital model, TCM physicians review the specific chemotherapy regimen and avoid herbs with known CYP interactions.

Anticoagulant effects: Some blood-activating (Huo Xue) herbs — Salvia (Dan Shen), Angelica (Dang Gui), Safflower (Hong Hua) — have mild anticoagulant properties. These are typically paused before surgery and during periods of thrombocytopenia to avoid bleeding risk.

Immune-modulating effects during immunotherapy: While immune-stimulating herbs like Astragalus are generally considered beneficial during chemotherapy, their use during immune checkpoint inhibitor therapy (PD-1/PD-L1 drugs) requires careful consideration. Excessive immune stimulation could theoretically exacerbate immune-related adverse events. Chinese hospitals with immunotherapy experience typically have protocols specifying which herbs are safe during immunotherapy cycles.

Gastrointestinal absorption effects: Some mineral-containing TCM preparations and high-fiber herbal decoctions can affect the absorption of oral chemotherapy drugs (capecitabine, erlotinib, etc.). Standard practice is to separate oral herb and drug administration by at least 2 hours.

The Safety Advantage of Institutional Integration

The critical point for international patients: these interactions are manageable when the TCM physician and the oncologist share information and coordinate timing. The danger arises when patients take self-prescribed herbal supplements without informing their oncologist — a common situation in countries where TCM and oncology operate in separate, unconnected systems.

In China's integrated model:

• TCM prescriptions are recorded in the same electronic medical record as chemotherapy orders
• Hospital pharmacists cross-check herbal and Western prescriptions for known interactions
• Herbal formulas are paused during critical treatment windows and resumed when safe
• Blood monitoring captures any unexpected effects that might indicate interaction

This systematic approach to safety is one of the strongest arguments for receiving integrative cancer care within China's hospital system rather than attempting to cobble together integration independently.

The Future of Integrative Oncology

China's integrative oncology model is not static. Several developments are shaping its future:

Precision TCM: Researchers at major Chinese universities are using genomic profiling, metabolomics, and artificial intelligence to identify which patients are most likely to benefit from specific herbal formulas — moving TCM from pattern-based prescribing toward precision medicine.

International collaboration: The CACA integrative guidelines are increasingly being shared with international oncology organizations. The 2024 China Integrative Oncology Conference (CCHIO) in Xi'an specifically addressed international data sharing and evidence standardization.

Botanical drug development: YIV-906's progression through FDA clinical trials — from ancient formula to potential FDA-approved botanical cancer drug — represents a template for future TCM-derived pharmaceuticals. If approved, it would be the first purely botanical drug authorized in the US for cancer treatment.

Digital health integration: Chinese hospitals are beginning to incorporate AI-driven herb-drug interaction checking systems, wearable devices that monitor qi gong practice adherence, and telemedicine platforms that allow remote TCM follow-up for international patients.

Next Steps for International Patients

If you are considering integrative cancer care in China, the practical path forward includes:

1. Gather your medical records — pathology reports, imaging, genetic testing, treatment history
2. Request a remote consultation — OriEast can arrange a telemedicine consultation with both an oncologist and TCM physician at a leading Chinese cancer center
3. Understand your treatment options — our guides on CAR-T therapy, proton therapy, and medical tourism logistics provide detailed information on specific treatments
4. Plan your trip — visa, accommodation, companion logistics, and follow-up care coordination
5. Communicate with your home oncologist — ensure your current treatment team is informed and can provide continuity of care

OriEast specializes in coordinating cancer care for international patients in China. We handle medical record translation, hospital selection, appointment coordination, accommodation, and in-country support — allowing you to focus on your health.

Medical Disclaimer: This article is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The clinical studies referenced are presented to illustrate the current state of research and do not guarantee individual outcomes. Cancer is a serious condition requiring individualized medical assessment. Do not discontinue prescribed treatments without consulting your treating oncologist. Individual results from integrative treatments may vary. OriEast facilitates access to healthcare services but does not provide direct medical care.